Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifamycin SV rectal enema placebo-controlled study in mild to moderate left-sided ulcerative colitis
2023-506917-23-00Phase 2Completed
- Sponsor
- Cosmo Pharmaceuticals
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis and ulcerative proctitis comparing Rifamycin SV sodium enema with Matching placebo enema (2 arms). Primary endpoint: Clinical remission at Week 6. Started Apr 2024; status: completed.
02
Drugs
rifamycin SV-MMX
03
Conditions
autoimmune colitisulcerative proctitis
Beyond the preview
Go deeper on 2023-506917-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506917-23-00.